UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 186

Sortiert nach

Standards in breast conservation and oncoplastic surgery

Breast (Edinburgh), 2021-04, Vol.56, p.S8

Fitzal, F.

2021

Volltextzugriff (PDF)

Extent of surgery post neoadjuvant – minimal or extensive?

Breast (Edinburgh), 2017-03, Vol.32, p.S14-S15

Fitzal, F

2017

Volltextzugriff (PDF)

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial

BMC cancer, 2020-05, Vol.20 (1), p.392-392, Article 392

2020

Volltextzugriff (PDF)

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Annals of oncology, 2015-02, Vol.26 (2), p.313-320

2015

Volltextzugriff (PDF)

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Annals of oncology, 2014-02, Vol.25 (2), p.339-345

2014

Volltextzugriff (PDF)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry

Breast (Edinburgh), 2022-08, Vol.64, p.127-133

2022

Volltextzugriff (PDF)

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial

British journal of surgery, 2021-04, Vol.108 (3), p.308-314

2021

Volltextzugriff (PDF)

109. Oncoplastic surgery

European journal of surgical oncology, 2012-09, Vol.38 (9), p.767-768

Fitzal, F

2012

Volltextzugriff (PDF)

Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival

Annals of surgical oncology, 2020-05, Vol.27 (5), p.1700-1707

2020

Volltextzugriff (PDF)

P192 Ptotic versus non ptotic breasts in nipple-sparing mastectomy and immediate prepectoral breast reconstruction

Breast (Edinburgh), 2023-04, Vol.68, p.S91-S92

2023

Volltextzugriff (PDF)

P177 Prepectoral versus subpectoral implant-based breast reconstruction: A systemic review and meta-analysis

Breast (Edinburgh), 2023-04, Vol.68, p.S86-S86

2023

Volltextzugriff (PDF)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

British journal of cancer, 2015-04, Vol.112 (8), p.1405-1410

2015

Volltextzugriff (PDF)

SA 6.1 - Standards in breast conservation and oncoplastic surgery

Breast (Edinburgh), 2021-04, Vol.56, p.S8-S8

Fitzal, F.

2021

Volltextzugriff (PDF)

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial

British journal of cancer, 2013-08, Vol.109 (3), p.589-596

2013

Volltextzugriff (PDF)

Local Therapy in Stage IV Breast Cancer Patients

Annals of surgical oncology, 2008-09, Vol.15 (9), p.2618-2618

Fitzal, F.

2008

Volltextzugriff (PDF)

P270 Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Breast (Edinburgh), 2023-04, Vol.68, p.S123-S124

2023

Volltextzugriff (PDF)

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

Annals of oncology, 2014-02, Vol.25 (2), p.366-371

2014

Volltextzugriff (PDF)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

British journal of cancer, 2012-01, Vol.106 (1), p.25-31

2012

Volltextzugriff (PDF)

SA 7.4 - Extent of surgery post neoadjuvant – setting: Estimating the extent of surgery

Breast (Edinburgh), 2019-03, Vol.44, p.S9-S9

Fitzal, F.

2019

Volltextzugriff (PDF)

Extent of surgery post neoadjuvant – setting: Estimating the extent of surgery

Breast (Edinburgh), 2019-03, Vol.44, p.S9

Fitzal, F.

2019

Volltextzugriff (PDF)

Brain metastases free survival differs between breast cancer subtypes

British journal of cancer, 2012-01, Vol.106 (3), p.440-446

2012

Volltextzugriff (PDF)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer

British journal of cancer, 2014-08, Vol.111 (5), p.837-842

2014

Volltextzugriff (PDF)

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer

British journal of cancer, 2013-09, Vol.109 (6), p.1522-1527

2013

Volltextzugriff (PDF)

Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna

Annals of oncology, 2019-05, Vol.30, p.iii9-iii9

2019

Volltextzugriff (PDF)

Analysing breast cosmesis

European journal of surgical oncology, 2009-02, Vol.35 (2), p.222-222

Fitzal, F

2009

Volltextzugriff (PDF)

1 – 25 von 186

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(179)
Mit Volltextzugriff
(170)

Publikationsform

Sprache

Englisch
(174)
Deutsch
(12)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(82)
Humans
(60)
Oncology
(53)
Female
(50)
Breast Cancer
(41)
Middle Aged
(37)
Surgery
(37)
Adult
(30)
Aged
(30)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Breast Neoplasms - Pathology
(24)
Breast Neoplasms - Drug Therapy
(22)
Breast Neoplasms - Surgery
(20)
Hematology, Oncology And Palliative Medicine
(20)
Medicin Och Hälsovetenskap
(19)
Prospective Studies
(19)
Tumors
(19)
Male
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Standards in breast conservation and oncoplastic surgery

Extent of surgery post neoadjuvant – minimal or extensive?

Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry

PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial

109. Oncoplastic surgery

Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival

P192 Ptotic versus non ptotic breasts in nipple-sparing mastectomy and immediate prepectoral breast reconstruction

P177 Prepectoral versus subpectoral implant-based breast reconstruction: A systemic review and meta-analysis

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

SA 6.1 - Standards in breast conservation and oncoplastic surgery

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial

Local Therapy in Stage IV Breast Cancer Patients

P270 Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

SA 7.4 - Extent of surgery post neoadjuvant – setting: Estimating the extent of surgery

Extent of surgery post neoadjuvant – setting: Estimating the extent of surgery

Brain metastases free survival differs between breast cancer subtypes

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer

Utilization and performance of the Prosigna® breast cancer prognostic gene signature assay at the Medical University of Vienna

Analysing breast cosmesis

Suchergebnisse filtern